Weight Management Peptides: Retatrutide, Cagrilintide & AOD-9604
Scientific overview of weight management peptides: retatrutide, cagrilintide, and AOD-9604, including mechanisms, study data, and research context.
Weight management research now includes several peptide strategies with different biological targets. Established GLP-1-based agents such as semaglutide and tirzepatide provide the clinical reference points, while newer candidates such as retatrutide and cagrilintide extend the field in different ways. AOD-9604 is often discussed separately because it does not belong to the incretin class.
This article compares three research peptides in the category: Retatrutide, Cagrilintide, and AOD-9604, with a focus on mechanism, published human data, and current development context.
Three Research Angles in Weight Management
Current peptide research in weight regulation can be grouped into three broad approaches:
Triple receptor agonism combines appetite-related incretin signaling with glucagon receptor activity. Retatrutide is the main example in this group.
Amylin-based signaling addresses satiety through pathways that differ from GLP-1 and GIP. Cagrilintide is being studied mainly as part of the CagriSema combination with semaglutide, although monotherapy data also exist.
Non-incretin lipolysis research includes compounds such as AOD-9604, a modified growth hormone fragment studied for metabolic effects outside the classic incretin framework.
Retatrutide - Triple Receptor Agonist
Retatrutide (LY-3437943) is a GLP-1/GIP/glucagon triple receptor agonist developed by Eli Lilly. It is being studied as a metabolic peptide that combines reduced energy intake with glucagon-linked effects on energy expenditure and liver fat metabolism.
First-ever triple-action weight management peptide targeting three receptors at once: GIP, GLP-1, and glucagon. Shown exceptional results in Phase 2 trials - up to 24% weight reduction. The most advanced metabolic peptide available.
Why Three Receptors?
Semaglutide and tirzepatide provide useful clinical benchmarks for this class. In STEP 1, semaglutide produced a mean body weight reduction of 14.9% after 68 weeks. In SURMOUNT-1, tirzepatide reached 20.9% at 72 weeks in the highest-dose group. Retatrutide adds glucagon receptor agonism to the GLP-1/GIP framework that tirzepatide already established.
The GLP-1 component contributes appetite reduction, slower gastric emptying, and glucose-dependent insulin secretion.
The GIP component is thought to contribute to glycemic control and may affect body composition, although the exact contribution remains an active area of research.
The glucagon component is relevant because it may increase energy expenditure and influence hepatic fat handling. That is one reason retatrutide is being studied not only for obesity, but also for metabolic liver disease.
Phase II Data: Retatrutide
In the highest-dose group of Lilly's Phase II obesity trial, mean body weight reduction reached approximately 24.2% at 48 weeks. This remains a notable Phase II result, but it should be interpreted as mid-stage trial data rather than as a stable long-term ceiling for the field.
Liver Fat Reduction
In a Phase II study in adults with obesity and MASLD, retatrutide reduced liver fat content substantially, with mean relative reductions reported up to 82.4% in treated groups. In the same study, up to 86% of participants in one dose group reached a liver fat level below 5%, which is a separate endpoint from the mean relative reduction. These findings support ongoing interest in retatrutide for liver-focused metabolic research, but they do not replace Phase III confirmation.
Study Status
Retatrutide is in Phase III clinical development. The headline weight-loss data most often cited still come from Phase II studies, so current interpretation should distinguish clearly between published mid-stage efficacy data and ongoing confirmatory trials.
AOD-9604 - GH Fragment in Metabolic Research
AOD-9604 is a modified fragment of human growth hormone corresponding to amino acids 176 to 191. It is usually discussed as a non-incretin research peptide because its proposed metabolic effects differ from the appetite-centered mechanisms of GLP-1, GIP, or amylin-based compounds.
Modified hGH fragment (176-191) studied for fat metabolism and lipolysis research. Interacts with beta-3 adrenergic receptors without growth-promoting effects.
Mechanism
Preclinical literature has described AOD-9604 as retaining some lipolytic and anti-lipogenic properties associated with the C-terminal region of growth hormone while not acting like full-length hGH across the classic growth hormone receptor axis. For that reason, it is more accurate to describe AOD-9604 as a GH-derived fragment with a distinct experimental profile, not as a simple proxy for full growth hormone signaling.
Unlike GLP-1-based compounds, AOD-9604 is not primarily studied for appetite suppression, delayed gastric emptying, or incretin-mediated glucose effects. The research interest is narrower and centers on whether GH-fragment biology can influence fat metabolism without typical growth-promoting effects.
Research Profile AOD-9604
Most of the evidence for AOD-9604 comes from preclinical studies. Human studies have generally suggested a favorable safety profile, but clinical efficacy for meaningful weight loss has been limited or inconsistent. Claims of clear fat-mass reduction without broader endocrine effects should therefore be stated cautiously and not treated as established clinical outcomes.
Research Context
AOD-9604 belongs to a mechanistically separate line of metabolic research. It may be useful when a research question aims to compare appetite-driven pathways with non-incretin approaches to fat metabolism, but the human evidence base is much thinner than for GLP-1-, GIP-, or amylin-related compounds.
Cagrilintide and the Amylin Pathway
Cagrilintide adds a third research angle in weight management. It is a long-acting analog in the amylin field and is described in current literature as a dual amylin and calcitonin receptor agonist. Amylin is co-secreted with insulin from pancreatic beta cells and contributes to satiety signaling and gastric emptying through pathways that are distinct from classic GLP-1 and GIP agonism.
Combination Research: CagriSema
The most advanced clinical program in this area is CagriSema, the combination of cagrilintide and semaglutide. In REDEFINE 1, the combination produced greater mean weight reduction than either component alone, which supports the idea that amylin-pathway signaling can complement GLP-1-based therapy.
Monotherapy vs Combination Status
Cagrilintide should be distinguished from CagriSema in status discussions. The combination program has advanced into Phase III, whereas references to "Phase III" should not be read as a blanket statement about cagrilintide monotherapy in isolation.
Comparison of Mechanisms of Action
| Property | Retatrutide | AOD-9604 | Cagrilintide |
|---|---|---|---|
| Mechanism | Triple receptor agonist | GH-derived fragment | Amylin-pathway analog |
| Receptors / pathway | GLP-1 + GIP + Glucagon | GH-fragment metabolic pathway under study | Amylin + calcitonin receptor activity |
| Appetite reduction | Yes | Not established as primary effect | Yes |
| Energy expenditure | Likely increased via glucagon component | Unclear in humans | Not primary mechanism |
| Lipolysis focus | Indirect metabolic contribution | Core research focus | No |
| Insulin-related effects | Glucose-dependent incretin effects | Not a primary mechanism | Satiety-related, indirect metabolic effects |
| Study status | Phase III | Preclinical plus limited human studies | Combination program in Phase III (CagriSema) |